Multiple myeloma
BCMA and GPRC5D CAR-T cells and bispecifics, and what is left after triple-class exposure.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 5 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for plasma cell myeloma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 4 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | Literature | Pathways | Clinical | genetic literature | Animal models | RNA expr. |
|---|---|---|---|---|---|---|---|---|---|
| CRBN cereblon | 0.71 | – | 0.43 | ||||||
| TNFRSF17 TNF receptor superfamily member 17 | 0.68 | – | 0.46 | ||||||
| TP53Peds RMTL tumor protein p53 | 0.67 | 0.55 | 0.77 | ||||||
| LIG4 DNA ligase 4 | 0.66 | 0.90 | – | ||||||
| KRAS KRas proto-oncogene, GTPase | 0.66 | – | 0.77 | ||||||
| CXCR4Peds RMTL C-X-C motif chemokine receptor 4 | 0.66 | – | 0.41 | ||||||
| FGFR3 fibroblast growth factor receptor 3 | 0.64 | – | 0.64 | ||||||
| NRAS NRAS proto-oncogene, GTPase | 0.64 | – | 0.78 | ||||||
| XPO1Peds RMTL exportin 1 | 0.64 | – | 0.46 | ||||||
| CD38Peds RMTL CD38 molecule | 0.63 | – | – | ||||||
| NR3C1 nuclear receptor subfamily 3 group C member 1 | 0.62 | – | – | ||||||
| RBX1 ring-box 1 | 0.62 | – | – | ||||||
| PSMB8 proteasome 20S subunit beta 8 | 0.62 | – | – | ||||||
| PSMA3 proteasome 20S subunit alpha 3 | 0.62 | – | – | ||||||
| PSMA4 proteasome 20S subunit alpha 4 | 0.62 | – | – | ||||||
| HDAC4 histone deacetylase 4 | 0.61 | – | 0.43 | ||||||
| CUL4A cullin 4A | 0.61 | – | – | ||||||
| ADRM1 ADRM1 26S proteasome ubiquitin receptor | 0.61 | – | – | ||||||
| PSMD4 proteasome 26S subunit ubiquitin receptor, non-ATPase 4 | 0.61 | – | – | ||||||
| PSMD14 proteasome 26S subunit, non-ATPase 14 | 0.61 | – | – | ||||||
| PSMB9 proteasome 20S subunit beta 9 | 0.61 | – | – | ||||||
| PSMB5 proteasome 20S subunit beta 5 | 0.61 | – | – | ||||||
| PSMB4 proteasome 20S subunit beta 4 | 0.61 | – | – | ||||||
| PSMB6 proteasome 20S subunit beta 6 | 0.61 | – | – | ||||||
| DDB1 damage specific DNA binding protein 1 | 0.61 | – | – | ||||||
| PSMD1 proteasome 26S subunit, non-ATPase 1 | 0.61 | – | – | ||||||
| PSMB7 proteasome 20S subunit beta 7 | 0.61 | – | – | ||||||
| PSMC6 proteasome 26S subunit, ATPase 6 | 0.61 | – | – | ||||||
| PSMB1 proteasome 20S subunit beta 1 | 0.61 | – | – | ||||||
| PSMA6 proteasome 20S subunit alpha 6 | 0.61 | – | – | ||||||
| PSMA5 proteasome 20S subunit alpha 5 | 0.61 | – | – | ||||||
| PSMB3 proteasome 20S subunit beta 3 | 0.61 | – | – | ||||||
| PSMD13 proteasome 26S subunit, non-ATPase 13 | 0.60 | – | – | ||||||
| PSMA2 proteasome 20S subunit alpha 2 | 0.60 | – | – | ||||||
| PSMD6 proteasome 26S subunit, non-ATPase 6 | 0.60 | – | – | ||||||
| PSMC2 proteasome 26S subunit, ATPase 2 | 0.60 | – | – | ||||||
| PSMA1 proteasome 20S subunit alpha 1 | 0.60 | – | – | ||||||
| PSMD8 proteasome 26S subunit, non-ATPase 8 | 0.60 | – | – | ||||||
| PSMC5 proteasome 26S subunit, ATPase 5 | 0.60 | – | – | ||||||
| PSMC3 proteasome 26S subunit, ATPase 3 | 0.60 | – | – | ||||||
| PSMA7 proteasome 20S subunit alpha 7 | 0.60 | – | – | ||||||
| PSMD12 proteasome 26S subunit, non-ATPase 12 | 0.60 | – | – | ||||||
| PSMB10 proteasome 20S subunit beta 10 | 0.60 | – | – | ||||||
| PSMD3 proteasome 26S subunit, non-ATPase 3 | 0.60 | – | – | ||||||
| SEM1 SEM1 26S proteasome subunit | 0.60 | – | – | ||||||
| PSMD7 proteasome 26S subunit, non-ATPase 7 | 0.60 | – | – | ||||||
| PSMB2 proteasome 20S subunit beta 2 | 0.60 | – | – | ||||||
| PSMB11 proteasome subunit beta 11 | 0.60 | – | – | ||||||
| PSMA8 proteasome 20S subunit alpha 8 | 0.60 | – | – | ||||||
| PSMC4 proteasome 26S subunit, ATPase 4 | 0.60 | – | – |
8 biomarkers in Multiple myeloma have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Multiple Myeloma”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 26 accepted items exist; the first 26 were read. This is the published evidence, not treatment advice.
- KRAS G12 level B
- BRAF V600E level B
- CTAG1B Overexpression level B
- CTAG2 Overexpression level B
- KRAS G12A level B
- KRAS G13 level B
- KRAS Q61 level B
- NRAS Mutation level B